Standard pricing rules often fail to convince payers when innovative, high-budget-impact medicines seek reimbursement. Türkiye addresses this gap through the Alternative Reimbursement Regulation: first published in February 2016 and updated in 2023, it opens the door to negotiated, contractual models between companies and the SGK outside the standard framework. This article examines the regulatory architecture, the model types, international practice, the evolution towards outcome-based agreements — and the three-phase methodology that ties them all together.
Why alternative models: the anatomy of the problem
Three features of innovative medicines strain standard payment systems. First, budget impact: therapies with annual per-patient costs in the hundreds of thousands of dollars shake annual budget slices in single-payment systems. Second, uncertainty: outside randomised trials, effectiveness, survival and progression data are limited; the payer asks, "if I pay and it doesn't work, then what?" Third, the reference-price problem: firms under international reference pricing risk exporting any Türkiye-specific discount to other markets.
Alternative models answer these three problems with three mechanisms: negotiated flexibility (stepping outside standard rules), confidentiality (net price and terms undisclosed) and risk sharing (compensation mechanisms when outcomes disappoint).
The 2016 regulation and 2023 update: the institutional frame
The GHS Alternative Reimbursement Regulation published in February 2016 established the legal basis for negotiating the terms of alternative reimbursement models between the SGK and companies. The regulation defines the model, application and evaluation processes, contract elements and the Institution's standing as a party. The 2023 update expanded scope: products supplied under named-patient programmes (NPP) — not yet licensed or commercialised in Türkiye but approved by major regulators — could be included in the models.
The regulation's most critical feature is confidentiality: rebate rates and payment terms in alternative models are not disclosed publicly. This lets a company offer net-price flexibility in Türkiye without disturbing its international reference pricing — the model's core logic. In practice, this confidentiality requires every party to the deal (company, institution, researchers, advisors) to govern information management contractually.
Model types: the spectrum from financial to outcome-based
1. Discount-based models
The simplest form: a negotiated additional discount off the list price, applied through invoicing or rebates. Quick to set up; but it shares no risk and corrects budget impact only modestly.
2. Price-volume threshold models
When sales volume crosses a defined threshold, an extra discount or rebate kicks in. This secures payer budget predictability; the firm protects margin in high-volume scenarios. Threshold design is sensitive to patient-number forecast accuracy.
3. Time-limited payment and payment-stop models
Payment runs for a defined period (e.g. until first response assessment); if response occurs, payment continues; if not, the company refunds or completes treatment free of charge. Oncology versions tied to progression checkpoints are common.
4. Outcome (benefit)-based agreements
Payment is tied to defined clinical endpoints (response rate, survival, defined score improvement). The most powerful and the hardest: endpoint measurement, data infrastructure and dispute mechanisms are required. Turkish practice shows growing interest but limited prevalence.
5. Pool/fund models
Payment comes from a budget pre-allocated to a disease group; companies contribute to the pool and excess costs are shared. They arise in rare diseases and very high-cost therapies.
International practice: what can Türkiye borrow?
- United Kingdom: NICE's Highly Specialised Technologies (HST) evaluations and managed access agreements allow payment while data accrue; sector-wide revenue-cap schemes (PPRS/VPS) are another instrument.
- Italy: AIFA has long run registry-integrated monitored agreements (piano di monitoraggio) with payback/loss-fund mechanisms, supported by the national rare-disease network (RAR).
- France: the CEPS sets prices provisionally under early-access programmes and finalises them with real-world data.
Two transfer lessons for Türkiye: (1) outcome-based agreements are unsustainable without registry infrastructure — the Italian model rests on a data backbone; (2) the cycle of provisional payment + data collection + finalisation (France/UK) secures both early patient access and payer uncertainty management. The 2023 update's NPP coverage can be read as Türkiye's counterpart to that cycle.
The three building blocks of outcome-based agreements
- Data infrastructure: patient tracking, registry design and real-world data supply determine deal quality. The better the endpoint is measured, the better both parties price the risk.
- Measurable endpoints: negotiable, verifiable, billing-linkable performance indicators. Aligning the definition of "response" with the clinical protocol prevents later disputes.
- Exit scenarios: price refund, treatment stop or free completion for non-responders, defined in the contract. "What if the patient discontinues?", "what if measurement fails?" must be answered upfront.
Points of attention in Turkish practice
In practice, alternative models enter the agenda as a continuation of the reimbursement-file evaluation: the file receives a favourable leaning at the technical committee, but with high budget impact the Institution signals openness to an alternative-model proposal. The model proposal should therefore be prepared as an integral annex to the file, resting on the same evidence structure. A second attention point is operational load: threshold tracking, rebate calculations, registry entries and reporting generate extra work for both parties; the deal's sustainability is tested against the cost of this operation. Third, duration and renewal: agreements are periodic; renewal negotiations require consistent data collection throughout the term.
The three-phase methodology: analysis → design → presentation and contract
Omega Arastirma's Public-Industry Alternative Working Models service manages the process in three phases:
- Phase I — Analysis: the product's budget impact, unmet need and alignment with payer priorities; building the evidence-based case for an alternative model. The negotiation space is mapped: which parameters allow flexibility, which are red lines?
- Phase II — Model design: rebate, threshold, time-limited payment or outcome-based? Simulations test the payer's acceptability range; each variant's consequences are computed across budget impact, company net revenue and patient access.
- Phase III — Presentation and contract: advisory-board maturation, model presentation to the Institution and contract-draft development. Data, measurement, dispute, confidentiality and renewal clauses are drafted in detail.
A preparation checklist for company strategy
- Is the budget-impact and unmet-need story for your product ready?
- Which model type are you flexible on — in which parameters do you have negotiation room?
- Can your registry/data infrastructure carry an outcome-based agreement?
- Who will run agreement operations (threshold tracking, rebates, reporting), on which system?
- Is your information-management protocol for confidentiality and reference-price risk defined?
Simulation: how a threshold model works
Thinking in numbers is the fastest way to understand model types. A fictional example: a product's annual per-patient cost is TRY 500,000; the payer agrees to pay list price up to 150 patients, an extra 15% rebate between 150-250, and an extra 25% beyond 250. If the company forecasts 180 patients, the first 150 bill at full price and the next 30 at a 15% rebate — expected net revenue is computed accordingly. If patients rise to 260, the last slice moves to 25% and average net price falls; the volume increase partly compensates total revenue. Even this simple arithmetic shows three strategic truths: (1) threshold design is asymmetrically sensitive to patient-number accuracy — a low forecast costs the company margin, a high one opens a budget gap; (2) the threshold points, not the rebate percentage, are the real negotiating table; (3) every threshold model signed without sensitivity analysis is condemned to produce surprises. The same logic extends to time-limited payment and outcome-based models: stress-test every model against patient-flow assumptions.
Contract clauses: a checklist
Alternative-model agreements carry risks different from standard procurement; before signature, check these provisions. Scope and party definitions: which product, indication, patient population; are subsidiaries and successors included? Payment mechanism: thresholds, rebate rates, refund calculation method, payment calendar and late interest. Data and measurement: which data source governs (payer records, company records, an independent registry); the resolution path for data mismatches. Disputes and corrections: objection windows, resolution process, mediation/litigation options. Confidentiality: scope, duration, remedy for breach; obligations flowing to third parties (consultants, researchers). Duration and renewal: term length, renewal conditions, early termination events. Pharmacovigilance and appropriateness: management of out-of-criteria use, notification duties. Public-law compliance: the agreement's conformity with legislation (SUT, procurement, public finance) and the adaptation obligation upon legislative change. This list is not the legal team's starting point; it is the negotiation table's agenda board.
Negotiation preparation: what do you bring to the payer table?
The common preparation set of successful alternative-model negotiations has four parts. First, the evidence dossier: clinical effectiveness, local cost data, unmet need — the standard file evidence is also the proposal's foundation. Second, budget-impact simulations: from the payer perspective, a map of budget impact across patient-number and rebate scenarios; the answer to "which proposal resolves the payer's budget concern by how much". Third, BATNA analysis: what if no deal — the cost to both sides of the product remaining listed, entering late, or not entering at all. Fourth, the map of internal payer dynamics: which commissions decide, which units carry which concern (budget, equity, precedent anxiety). With all four prepared, negotiation moves from price-offer repetition into a joint problem-solving rhythm — in practice the fastest route to agreement.
A glossary: the language of alternative payment models
The shared meanings of the terms used in model negotiations: Risk sharing: distribution of the financial consequences of outcome uncertainty between company and payer; the umbrella concept. Pay for performance (P4P): payment tied to defined clinical performance indicators. Payment cap/stop: a per-patient or aggregate ceiling; beyond it the company carries the cost. Time-limited payment: payment until response assessment; refund or free completion on non-response. Price-volume agreement (PVA): rebate/refund mechanisms tied to volume thresholds. Registry: the agreement's data backbone — standard-form patient follow-up. Budget impact: the annual incremental load on the payer budget from listing. Net versus list price: the realised amount governing confidential negotiation versus the official amount. Renewal: renegotiation of the agreement in the light of data at term-end. BATNA: best alternative to a negotiated agreement — the cost of each side's walk-away option. This glossary is the precondition of speaking one language at the payer table and inside the company.
The map of internal decision-making: whose table does the proposal reach?
A proposal's fate cannot be managed without knowing the payer's decision route. The typical flow: the file passes technical committee assessment; clinical suitability is approved but budget impact is found high; the item moves to the reimbursement commission with a note "evaluate alternative model"; pricing/negotiation units contact the company; the draft agreement clears legal and senior management; the process completes with budget/planning approval. Each station carries a different concern: technical committee asks clinical rationale; pricing asks net price and budget; legal asks statutory compliance; senior management asks precedent effect. Company preparation must therefore be multi-layered against this concern map: the clinical dossier alone is insufficient; financial simulations and legal proposal texts must sit in the same package. Knowing the map ensures the proposal reaches the right people, in the right language, in the right order.
Why deals fail: how agreements break
International experience shows alternative-model agreements weakening for three reasons. Reason 1 — unmeasurable endpoints: when the outcome-based definition of "response" falls into clinical grey zones, parties interpret data differently and trust breaks. Remedy: protocol-annexed, independently verifiable endpoints. Reason 2 — commitments without data infrastructure: the company promises outcomes before building the registry; lost patients and missing measurements render the deal unworkable. Remedy: pilot period and registry investment completed upfront. Reason 3 — operational fatigue: refund calculations, reconciliations and reporting paralyse the process; the agreement stays on paper. Remedy: automated data flows and a lean calendar (e.g. two reconciliations a year). The shared lesson: a deal succeeds not on signature day but in the month it operates. In Turkish practice too, companies presenting model proposals together with operational reality earn a place in the payer's memory as reliable partners.
Step by step: preparing a model proposal
Preparation runs in eight steps. Step 1 — Ground analysis: the file's current status, technical-committee signals, budget-impact magnitude and the payer's openness to model language. Step 2 — Evidence inventory: availability of clinical data, local cost data, registry/real-world data; can gaps be closed, and in what time? Step 3 — Model-type selection: candidate models (rebate, threshold, time-limited, outcome-based, pool) listed with feasibility scores. Step 4 — Simulations: patient-flow and budget-impact scenarios for the 2-3 candidates; company net revenue and payer budget impact on the same chart. Step 5 — Endpoint and measurement protocol: for outcome-based candidates, the response definition, registry form and verification method. Step 6 — Advisory-board maturation: testing model assumptions and acceptability limits with experts. Step 7 — Proposal package: executive summary, technical annexes, simulations, contract draft and operations plan. Step 8 — Payer presentation and negotiation plan: presentation order, Q&A preparation, negotiation space and walk-away thresholds. The process averages 8-12 weeks and is most efficient when run in step with the file's evidence.
A registry infrastructure guide: the model's data backbone
The heart of outcome-based and monitored agreements is the registry; construction has five stages. Stage 1 — Minimum data set: diagnosis, baseline characteristics, treatment, response measurements, resource use; a "collect everything" approach kills entry. Stage 2 — Form and system design: forms embedded in the centre's daily practice (e-Nabız/hospital-system compatible); ideally single-point digital entry. Stage 3 — Centre and physician training: form practice, measurement timing and data-quality rules. Stage 4 — Quality-control loop: missing/inconsistent-data reports, centre-level feedback, correction timelines. Stage 5 — Reporting layer: queries feeding the agreement's refund/threshold calculations directly; a payer-company reconciliation format. This backbone retains value independent of any single deal: the registry is the permanent source of the product's real-world evidence and produces the input of the next indication/expansion file. Registry investment is therefore not the cost of one agreement but the product's evidence capital in Türkiye.
Sources and key takeaways
Core sources: the GHS Alternative Reimbursement Regulation (2016; 2023 update); SGK legislation and announcements; international practice literature (NICE managed access, AIFA monitoring agreements, CEPS early access). Recommended monitoring: regulatory amendments, SGK commission decisions and legal briefings; HTA agencies' contract templates as precedent. Our key takeaways: (1) the model proposal is an integral annex of the file — present it with the evidence; (2) confidentiality is the core of net-price flexibility and reference protection; (3) do not offer outcome-based terms without the three building blocks (data infrastructure, measurable endpoint, exit scenarios); (4) a deal succeeds in the month it operates, not on signature day — the operations plan belongs in the package; (5) knowing the payer's internal decision map ensures the proposal is delivered in the right language and order.
Practical summary: the access team's worksheet
Compressing this article to a single page: the case for an alternative model is budget impact failing the standard or high uncertainty; the proposal's foundation is the file's evidence; negotiation runs under confidentiality. Your worksheet holds three boxes. Box 1 — Readiness: is the evidence inventory complete (local cost data, response measurement, registry infrastructure)? Has the BATNA analysis run? Is the payer's internal decision map clear? Box 2 — Design: which model type (rebate, threshold, time-limited, outcome-based, pool); has the acceptability range been simulation-tested; is the worst-case table ready? Box 3 — Operation: are the measurement protocol, reconciliation calendar, refund-calculation system and renewal plan defined? An empty box means a rushed proposal — filling the box is cheaper than stepping back at the table. And remember: the measure of success is not the deal's duration but the number of months it actually operates.
Conclusion
Alternative reimbursement models are the most flexible answer to the access problem of innovative medicines in Türkiye; success, however, depends on the proposal resting on evidence, the model being operationally sustainable, and the negotiation space being well mapped. The global shift from discount-volume financial models to outcome-based agreements will reward companies that invest in data infrastructure in Türkiye too. To build your alternative-model strategy end-to-end, see our Public-Industry Alternative Working Models service and reach out.